Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

医学 外科 危险系数 置信区间 胃肠病学 内科学
作者
Alexander E. Perl,Richard A. Larson,Nikolai A. Podoltsev,Stephen A. Strickland,Eunice S. Wang,Ehab Atallah,Gary J. Schiller,Giovanni Martinelli,Andreas Neubauer,Jorge Sierra,Pau Montesinos,Christian Récher,Sung‐Soo Yoon,Naoko Hosono,Masahiro Onozawa,Shigeru Chiba,Hee‐Je Kim,Nahla Hasabou,Qiaoyang Lu,Ramón V. Tiu,Mark J. Levis
出处
期刊:Blood [Elsevier BV]
卷期号:139 (23): 3366-3375 被引量:92
标识
DOI:10.1182/blood.2021011583
摘要

Abstract The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation–positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to clarify the long-term treatment effects and safety of gilteritinib in these patients with AML. At the time of this analysis, the median survival follow-up was 37.1 months, with deaths in 203 of 247 and 97 of 124 patients in the gilteritinib and SC arms, respectively; 16 gilteritinib-treated patients remained on treatment. The median overall survival for the gilteritinib and SC arms was 9.3 and 5.6 months, respectively (hazard ratio, 0.665; 95% confidence interval [CI], 0.518, 0.853; two-sided P = .0013); 2-year estimated survival rates were 20.6% (95% CI, 15.8, 26.0) and 14.2% (95% CI, 8.3, 21.6). The gilteritinib-arm 2-year cumulative incidence of relapse after composite complete remission was 75.7%, with few relapses occurring after 18 months. Overall, 49 of 247 patients in the gilteritinib arm and 14 of 124 patients in the SC arm were alive for ≥2 years. Twenty-six gilteritinib-treated patients remained alive for ≥2 years without relapse; 18 of these patients underwent transplantation (hematopoietic stem cell transplantation [HSCT]) and 16 restarted gilteritinib as post-HSCT maintenance therapy. The most common adverse events of interest during years 1 and 2 of gilteritinib therapy were increased liver transaminase levels; adverse event incidence decreased in year 2. Thus, continued and post-HSCT gilteritinib maintenance treatment sustained remission with a stable safety profile. These findings confirm that prolonged gilteritinib therapy is safe and is associated with superior survival vs SC. This trial was registered at www.clinicaltrials.gov as #NCT02421939.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
汉堡包应助NOTHING采纳,获得10
1秒前
SYLH应助科研通管家采纳,获得50
1秒前
quhayley应助科研通管家采纳,获得10
1秒前
爆米花应助科研通管家采纳,获得10
1秒前
坦率的匪应助科研通管家采纳,获得10
2秒前
田様应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得50
2秒前
orixero应助科研通管家采纳,获得10
2秒前
SYLH应助科研通管家采纳,获得50
2秒前
思源应助科研通管家采纳,获得10
2秒前
2秒前
隐形曼青应助科研通管家采纳,获得10
2秒前
czh应助科研通管家采纳,获得10
2秒前
赘婿应助科研通管家采纳,获得10
2秒前
华仔应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
3秒前
SYLH应助科研通管家采纳,获得50
3秒前
大模型应助科研通管家采纳,获得10
3秒前
3秒前
斯文败类应助Keyl采纳,获得10
3秒前
褪黑素应助科研通管家采纳,获得10
3秒前
完美世界应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
3秒前
努力科研霸王龙完成签到 ,获得积分10
4秒前
nns关闭了nns文献求助
4秒前
田様应助jiabaoyu采纳,获得10
5秒前
脑洞疼应助林林林林采纳,获得10
5秒前
xiaoxiao完成签到,获得积分10
5秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021